RXST

Rxsight INC

-$138.3M

Net Activity

Institutions Holding

164

Popularity Rank

#3374

Avg Weight

0.04%

Total Value

$233.8M

Ownership Trend

164 institutions currently hold RXST, with 93 net buyers and 85 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

85

Net Buying Institutions

93

Key Holders

Key Holders

Top 5 by Value

BI
BlackRock, Inc.
$19.6M
MM
Millennium Management LLC
$12.7M
AP
Artisan Partners Limited Partnership
$12.7M
NH
Nomura Holdings INC
$12.3M
NS
No Street GP LP
$12.3M

Top 5 by Conviction

VP
Vitruvian Partners LLP
1.54%
BM
Bridger Management, LLC
1.20%
NS
No Street GP LP
0.82%
GP
Grandeur Peak Global Advisors, LLC
0.67%
CL
Carnegie Lake Advisors LLC
0.38%
View all 164 holding institutions

Quarterly Activity

Recent Activity

+$144.0M

Total Buy Value

$170.6M

Total Sell Value

New buy29
Trim53
Add64
Sold out32

93

Net Buyers

85

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

3

Filings (14d)

Data as of 2026-07-15
2026-07-15

RxSight is shaking up its leadership. Dr. Ron Kurtz, who has led the company as President and CEO since 2016, is moving to the Chief Medical Officer role. The company has appointed Aziz Mottiwala, a veteran commercial executive from Allergan and Tarsus Pharmaceuticals, as the new President and CEO starting July 20. To get him on board, the board approved a compensation package including a $750,000 base salary and $14 million in equity inducement awards.

View Full Filing (SEC EDGAR)
2026-07-06

RxSight, Inc. filed an 8-K on July 6, 2026, stating that it issued a press release with preliminary unaudited results for the second quarter. The press release is attached as Exhibit 99.1. No specific financial figures were included in this 8-K filing.

View Full Filing (SEC EDGAR)
2026-07-06

RxSight entered into a collaboration with Alcon to combine its Light Adjustable Technology with Alcon's multifocal IOLs. The deal includes a $60 million upfront payment, up to $140 million in milestone payments, and 30% royalties on net sales. RxSight will manufacture the lenses and handle U.S. regulatory approvals and LDD installations.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding RXSIGHT INC (RXST)?
Major stakeholders currently include BlackRock, Inc. ($19.6M), Millennium Management LLC ($12.7M), Artisan Partners Limited Partnership ($12.7M). Based on the latest 13F filings, there are a total of 164 tracked investment funds and institutions maintaining positions in RXST.
What is the overall institutional sentiment toward RXST recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $138.3M, driven by 93 managers accumulating shares while 85 reduced their exposure.
Which institutions have been selling or reducing their RXST positions?
In the latest period, 53 funds trimmed their holdings, and 32 managers completely exited their positions. The aggregate reported sell value was $170.6M.
Are there any notable investors adding RXST to their portfolios?
Yes, buying activity remains notable. 29 institutions opened new positions in {ticker}, and 64 existing holders added to their shares. The total reported buy value for the quarter amounted to $144.0M.

Related Stocks

Trending Institutional Adds

The most-added stocks by 13F institutions this quarter

MSFT

Microsoft CORP

Institutions Holding

6,150

Total reported value

$2.1T

3245 13F institutions increased their position this quarter

View detail
AMZN

Amazon.com INC

Institutions Holding

5,957

Total reported value

$1.5T

3028 13F institutions increased their position this quarter

View detail
NVDA

Nvidia CORP

Institutions Holding

5,764

Total reported value

$3.0T

2743 13F institutions increased their position this quarter

View detail